10 likes | 161 Views
Durability of Effect in Double-blind Phase. Item. Active treatment. Placebo. value. P. 25% of patients had LTR. By day 34. By day 7. <0.0001. LTR by end of study. 32% of patients. 61% of patients. <0.0001. Worsening fatigue (MAF. By day 119. By day 27. <0.0001. scale).
E N D
Durability of Effect in Double-blind Phase Item Active treatment Placebo value P 25% of patients had LTR By day 34 By day 7 <0.0001 LTR by end of study 32% of patients 61% of patients <0.0001 Worsening fatigue (MAF By day 119 By day 27 <0.0001 scale) Worsening in Overall Sleep Problems Index By day 42 By day 14 <0.0001 (MOS - sleep scale) Presented at EULAR 2007.